Class-Specific Considerations
Source: Cytiva
Here, BioMarin's Nimi Chhina explains the class-specific considerations for cell and gene therapy products that industry and regulators alike can collectively consider to drive policy development.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Cytiva
This website uses cookies to ensure you get the best experience on our website. Learn more